A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) plus Zanubrutinib (BGB-3111) Compared with Venetoclax plus Acalabrutinib in Patients with Previously Untreated Chronic Lymphocytic Leukemia
Clinical Trial Grant
Awarded By
BeOne Medicines USA, Inc.
Start Date
March 30, 2026
End Date
March 22, 2031
Awarded By
BeOne Medicines USA, Inc.
Start Date
March 30, 2026
End Date
March 22, 2031